{"entity":{"id":"paper-konoplya-academic-cd19-car-t-lymphoma-belarus-front-oncol-2026","kind":"paper","name":"Academic CD19 CAR T-cell therapy for relapsed B-cell lymphoma at Belarus's national cancer centre","aka":[],"tldr":"Seventy-six people with relapsed or refractory B-cell lymphoma treated at the N.N. Alexandrov National Cancer Centre with an academic, non-commercial CAR T-cell product had a 57.5% complete response rate, and 67% were alive at four years.","summary":"Published as \"Academic anti CD19 CAR-T cell therapy for relapsed/refractory B-cell lymphomas in real-world clinical practice: a prospective cohort study\". From June 2021 to December 2025 the trial (NCT07524816) enrolled 76 patients aged 23 to 68 at the N.N. Alexandrov National Cancer Centre of Belarus, treated with an anti-CD19 CAR T-cell product made with a lentiviral vector. The authors' rationale is that commercial products cost too much for routine use.","asOf":"2026-11-11","links":[{"label":"Front Oncol 2026","url":"https://doi.org/10.3389/fonc.2026.1862517"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/42539439/"},{"label":"ClinicalTrials.gov: NCT07524816","url":"https://clinicaltrials.gov/study/NCT07524816"}],"tags":[],"related":[],"cancers":["non-hodgkin-lymphoma","follicular-lymphoma"],"sections":[],"technologies":["car-t"],"targets":[],"drugs":[],"companies":[],"institutions":["alexandrov-national-cancer-centre-belarus"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"journal":"Frontiers in Oncology","year":2026,"doi":"10.3389/fonc.2026.1862517","pmid":"42539439","authors":"Konoplya NE, Doroshenko TM, Zharkova KY, et al.","paperType":"real-world","findings":["Complete response was achieved in 57.5% of patients, and in 83.3% of those with follicular lymphoma.","Four-year event-free survival was 46.2% and four-year overall survival 67%.","Cytokine release syndrome occurred in 43.4% (grade 3 or higher in 2.6%) and neurotoxicity in 26.3% (grade 3 or higher in 5.3%)."],"whatItMeans":"Belarus offers CAR T-cell therapy through an academic product rather than a commercial one; the authors describe it as the only option where commercial products are not accessible.","caveats":["Single-centre cohort without a comparison group.","Median follow-up for the whole cohort was 7.85 months."],"participants":76},"route":"/key-papers/paper-konoplya-academic-cd19-car-t-lymphoma-belarus-front-oncol-2026/","neighbours":{"cancer":[{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"institution":[{"id":"alexandrov-national-cancer-centre-belarus","kind":"institution","name":"N.N. Alexandrov National Cancer Centre of Belarus","route":"/institutions/alexandrov-national-cancer-centre-belarus/"}]}}